Suppr超能文献

阿巴西普起始治疗后蛋白尿减少速度揭示其在激素抵抗型微小病变病中的疗效

Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept
.

作者信息

Dado David, Parikh Samir, Ayoub Isabelle, Rovin Brad, Nadasdy Tibor, Hebert Lee

出版信息

Clin Nephrol. 2018 May;89(5):376-380. doi: 10.5414/CN109290.

Abstract

A unique characteristic of the response of minimal-change disease (MCD) or focal and segmental glomerulosclerosis (FSGS) to steroid therapy is that the remission of proteinuria occurs quickly, for example, within 4 - 6 weeks of the onset of steroid therapy, even in those with severe nephrotic syndrome. Remission of proteinuria in MCD and FSGS can also occur spontaneously (not steroid induced). However, spontaneous remission usually proceeds over several months or longer. Recently, there have been several reports that abatacept can induce proteinuria remission in MCD and FSGS. These claims, however, are dubious because either the remission occurred slowly over several months of abatacept therapy, or remission occurred within a few weeks of abatacept therapy, but the patient was also receiving therapies that could have accounted for the remission of proteinuria. Our case is unique in that his severe steroid- and cyclosporine-resistant MCD remitted acutely while receiving abatacept, and there was no other plausible explanation for the acute remission of his MCD.
.

摘要

微小病变病(MCD)或局灶节段性肾小球硬化症(FSGS)对类固醇治疗反应的一个独特特征是蛋白尿缓解迅速,例如,在类固醇治疗开始后的4 - 6周内,即使是患有严重肾病综合征的患者也是如此。MCD和FSGS中的蛋白尿缓解也可能自发发生(非类固醇诱导)。然而,自发缓解通常需要数月或更长时间。最近,有几份报告称阿巴西普可诱导MCD和FSGS中的蛋白尿缓解。然而,这些说法值得怀疑,因为要么缓解在阿巴西普治疗的几个月内缓慢发生,要么在阿巴西普治疗的几周内发生缓解,但患者也在接受可能导致蛋白尿缓解的其他治疗。我们的病例很独特,因为他严重的类固醇和环孢素抵抗性MCD在接受阿巴西普治疗时急性缓解,且他的MCD急性缓解没有其他合理的解释。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验